Newsroom

Servier Appoints David K. Lee to Executive Committee

Servier Announces Expansion of its Tibsovo (ivosidenib) Development Program Investigating its Safety and Efficacy in Patients Living with IDH1-Mutated Cancers in Both Hematological Malignancies and Solid Tumors

Servier Partners With Local Cancer Center to Support Research Graduate Students in the Boston Area